Inventor · disambiguated record
Willem Meindert De Vos
Also filed as: DE VOS WILLEM · DE VOS WILLEM M · DE VOS WILLEM MEINDERT
19 granted patents·34 pending applications·112 citations·filing 1992–2025
93Inventor score
Files withUNIV CATHOLIQUE LOUVAIN12UNIV WAGENINGEN11ACAD MEDISCH CT6CAELUS PHARMACEUTICALS B V5DE VOS WILLEM MEINDERT2
Top patents by PatentIndex Score
53 records- 0192US9623055B2Method for preventing and/or treating insulin resistanceACAD MEDISCH CT·Filed 2016·Granted Apr 18, 2017·21 cites·24 claims
- 0287US9433650B2Method for preventing and/or treating insulin resistanceNIEUWDORP MAX·Filed 2012·Granted Sep 6, 2016·21 cites·6 claims
- 0386US10731142B2Thermostable Cas9 nucleasesPURAC BIOCHEM BV·Filed 2016·Granted Aug 4, 2020·5 cites·17 claims
- 0484US10736924B2Use of pasteurized Akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2016·Granted Aug 11, 2020·2 cites·14 claims
- 0582US10988509B2Method of culturing AkkermansiaUNIV WAGENINGEN·Filed 2016·Granted Apr 27, 2021·2 cites·13 claims
- 0680US2025288622A1Use of akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2025·Application pending·0 cites
- 0780US2025288621A1Use of akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2025·Application pending·0 cites
- 0876US11534465B2Fecal matter for treatment of autoimmune diseasesACAD MEDISCH CT·Filed 2019·Granted Dec 27, 2022·2 cites·23 claims
- 0976US10806758B2Methods for culturing and preserving Eubacterium hallii and treating disease and preparation thereofCAELUS PHARMACEUTICALS B V·Filed 2017·Granted Oct 20, 2020·2 cites·20 claims
- 1075US10857189B2Compositions and methods for preventing and/or treating vitamin B12 deficiencyCAELUS PHARMACEUTICALS B V·Filed 2017·Granted Dec 8, 2020·1 cites·21 claims
- 1174US10738089B2Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic statusUNIV WAGENINGEN·Filed 2016·Granted Aug 11, 2020·1 cites·26 claims
- 1273US2020237832A1Use of akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2019·Application pending·0 cites
- 1373US2020237833A1Use of akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2019·Application pending·0 cites
- 1473US2021393704A1Use of akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2021·Application pending·0 cites
- 1572US8445426B2Peptides and methods for producing themDE VOS WILLEM MEINDERT·Filed 2009·Granted May 21, 2013·6 cites·16 claims
- 1672US2021322489A1Use of akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2021·Application pending·0 cites
- 1770US11202807B2Bacterial speciesUNIV WAGENINGEN·Filed 2017·Granted Dec 21, 2021·1 cites·7 claims
- 1866US2020155616A1Use of akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2019·Application pending·0 cites
- 1966US2020121737A1Use of akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2019·Application pending·0 cites
- 2064US2019282630A1Use of akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2019·Application pending·0 cites
- 2163US2021188923A1Method of culturing akkermansiaUNIV WAGENINGEN·Filed 2021·Application pending·0 cites
- 2262US11802277B2Thermostable Cas9 nucleasesUNIV WAGENINGEN·Filed 2020·Granted Oct 31, 2023·0 cites·21 claims
- 2362US2025302807A1Intervention strategy for prevention or treatment of diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular diseaseACAD MEDISCH CT·Filed 2025·Application pending·0 cites
- 2461US11466057B2Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic statusUNIV WAGENINGEN·Filed 2020·Granted Oct 11, 2022·0 cites·7 claims
- 2560US5594103ALantibiotics similar to nisin aSTICHTING NL I ZUIVELONDERZOEK·Filed 1992·Granted Jan 14, 1997·18 cites·2 claims
- 2659US11426436B2Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseasesUNIV WAGENINGEN·Filed 2020·Granted Aug 30, 2022·0 cites·8 claims
- 2759US2015306152A1Use of akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2013·Application pending·0 cites
- 2858US2023181531A1Intervention strategy for prevention or treatment of diabetes mellitus, autoimmune disease, inflammatory disease or cardiovascular diseaseACAD MEDISCH CT·Filed 2021·Application pending·0 cites
- 2957US2025025517A1Prevention or treatment of hepatic steatosisCAELUS PHARMACEUTICALS B V·Filed 2022·Application pending·0 cites
- 3054US2023364164A1Fecal matter for preventing or treating intestinal microbiome aberrations in cesarean section-born infantsCAELUS PHARMACEUTICALS B V·Filed 2021·Application pending·0 cites
- 3153US2023201271A1Fecal matter for treatment of cachexiaACAD MEDISCH CT·Filed 2021·Application pending·0 cites
- 3253US2012238468A1Methods for diagnosing irritable bowel syndromeTUK LAMBERTUS·Filed 2010·Application pending·0 cites
- 3353US2023145426A1Particles comprising inulin for use as medicament or supplementWHOLEFIBER HOLDING B V·Filed 2021·Application pending·0 cites
- 3452US5928946ALactic acid bacteria producing lantibiotics similar to nisin ASTICHTING NL I ZUIVELONDERZOEK·Filed 1996·Granted Jul 27, 1999·13 cites·10 claims
- 3552US2023265131A1Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic statusUNIV WAGENINGEN·Filed 2021·Application pending·0 cites
- 3651US2015307924A1Methods for diagnosing irritable bowel syndromeAAK PATENT B V·Filed 2015·Application pending·0 cites
- 3750US2024269197A1Insulin-sensitizing agent and butyrate-producing bacteriumCAELUS PHARMACEUTICALS B V·Filed 2022·Application pending·0 cites
- 3850US2021015876A1Use of pasteurized akkermansia for treating metabolic disordersUNIV CATHOLIQUE LOUVAIN·Filed 2020·Application pending·0 cites
- 3949US2011123977A1Method for taking a plurality of samplesDSM IP ASSETS BV·Filed 2008·Application pending·0 cites
- 4048US2022228105A1Bacterium comprising myo-inositol to propionate pathwayUNIV WAGENINGEN·Filed 2020·Application pending·0 cites
- 4146US2007161928A1Sampling device for in vivo sampling of liquids from the gastrointestinal tract, process for the production thereof and mould or mask for use in the production processSTICHTING TECHNOLOGISCH TOP IN·Filed 2006·Application pending·0 cites
- 4244US2008248553A1Production of Bioavailable Folic AcidCAMPINA BV·Filed 2008·Application pending·0 cites
- 4343US5914248AMethod for controlling the gene expression in lactic acid bacteriaSTICHTING NL INSTITUUT VOOR DE·Filed 1995·Granted Jun 22, 1999·16 cites·22 claims
- 4443US2006205051A1Process for anaerobic oxidation of methaneSTAMS ALFONS J M·Filed 2003·Application pending·0 cites
- 4538US11452746B2Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseasesUNIV WAGENINGEN·Filed 2016·Granted Sep 27, 2022·0 cites·19 claims
- 4636US2008118943A1Bacteria that Naturally Overproduce FolateCSM NEDERLAND BV·Filed 2006·Application pending·0 cites
- 4735US2009004148A1Novel ProbioticUNIV WAGENINGEN·Filed 2006·Application pending·0 cites
- 4834US2004214261A1Production of bioavailable folic acidFiled 2002·Application pending·0 cites
- 4933US2017252421A1Compounds against ralstonia pickettii for use in the treatment of insulin resistance, and method of diagnosis of insulin resistanceACAD MEDISCH CT·Filed 2015·Application pending·0 cites
- 5031US2008219960A1Novel Efficient Production Process for Capsular Polysaccharides of Pathogenic Grampositive Bacteria by Heterologous Expression and Secretion of Complex Polysaccharides in Non-Pathogenic, Non-Invasive Gram-Positive BacteriaNIEROP GROOT MASJA NATHALIE·Filed 2005·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Willem Meindert De Vos files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →